Cannabichromene

Discovery

Cannabichromene was isolated and structurally characterized in 1966 by two independent groups working concurrently. Yechiel Gaoni and Raphael Mechoulam identified it in Egyptian hashish at the Weizmann Institute,^[3] extending Mechoulam's landmark 1964 elucidation of THC to a second major cannabinoid class. Simultaneously, Ulrich Claussen, Friedrich Von Spulak, and Friedrich Korte extracted CBC from hemp — the convergent discovery establishing it as the third recognized phytocannabinoid alongside THC and CBD.

Scientific significance

The first systematic biological study, conducted by Turner and ElSohly in 1981, established three foundational findings: CBC was the second most abundant cannabinoid in drug-type cannabis, its anti-inflammatory activity exceeded the NSAID phenylbutazone, and it possessed strong antibacterial properties.^[4] These results positioned CBC as pharmacologically significant despite its lack of psychoactivity — a profile that would take decades to fully investigate.

Modern research

Pharmacological interest revived in the 2010s when De Petrocellis and colleagues established CBC as a potent TRPA1 agonist and NAAA inhibitor,^[1] redirecting research away from CB1/CB2 paradigms toward non-canonical cannabinoid pathways. Subsequent work identified GABA_A positive allosteric modulation as a second major mechanism,^[2] and anti-inflammatory, analgesic, and anti-seizure properties were demonstrated in rodent models. As of 2026, CBC remains one of the most pharmacologically characterized phytocannabinoids to lack any completed human clinical data.

Structural class

CBC belongs to the chromene (benzopyran) subclass of phytocannabinoids. It shares the C₂₁ terpenophenolic scaffold common to all major cannabinoids derived from cannabigerolic acid, but its final biosynthetic cyclization produces a chromene ring rather than THC's cyclohexane system.^[8] This structural divergence is the basis for CBC's non-psychoactive profile.

The pentyl side chain and chromene ring are critical pharmacophores for antibacterial activity, particularly against methicillin-resistant Staphylococcus aureus (MRSA).^[9]

Molecular structure

The molecule features a resorcinol ring bearing a pentyl side chain at C-7, fused to a pyran ring with a 4-methylpent-3-enyl substituent and geminal methyl group at C-2. The chromene double bond between C-3 and C-4 distinguishes CBC from cannabicyclol (CBL), its photoisomerization product formed when this bond undergoes intramolecular [2+2] cycloaddition.

Stereochemistry

CBC occurs in cannabis as a scalemate — a non-racemic mixture of enantiomers whose ratio varies by strain. The enantiomeric composition is genetically determined, linked to differential expression of CBCA synthase isoforms.^[10] The biological activity of individual CBC enantiomers has not been independently studied, representing a significant pharmacological gap.

Physical properties and stability

CBC is a viscous oil at room temperature with a boiling point of approximately 220°C at reduced pressure. Its lipophilic character and molecular planarity facilitate intestinal lymphatic transport during oral absorption.^[11]

Stability is a practical concern: CBC converts to cannabicyclol under acidic conditions or prolonged UV exposure.^[12] Storage in neutral, light-protected conditions prevents this degradation.

Natural occurrence

CBC occurs in Cannabis sativa as the decarboxylation product of cannabichromenic acid (CBCA). CBCA is the first cannabinoid to accumulate in seedlings after germination,^[13] preceding both THCA and CBDA — a pattern suggesting a developmental or protective role in early plant growth.

In mature drug-type cannabis, CBC was historically the second most abundant cannabinoid,^[4] though modern high-THC cultivars have shifted this ranking. The propyl homolog cannabichromevarin (CBCV) also occurs naturally, and CBC content varies across chemotypes consistent with independent allelic control of the CBCA synthase locus.^[14]

Mechanism of action

CBC's pharmacology operates almost entirely outside the classical CB1/CB2 cannabinoid receptor system — a distinguishing feature among major phytocannabinoids. It exhibits negligible CB1 affinity and does not produce intoxication or THC-like effects in animal models.^[5][6]

The primary mechanism is TRPA1 agonism followed by channel desensitization. CBC activates TRPA1 channels on pain-sensing neurons, producing initial excitation followed by prolonged functional silencing.^[1] This desensitization underlies CBC's analgesic and anti-inflammatory effects, including suppression of intestinal hypermotility.^[15]

The second major mechanism is GABA_A positive allosteric modulation. CBC enhances GABA-mediated inhibitory currents by binding at a site on the β2 subunit (valine-436) distinct from the benzodiazepine pocket.^[2] This novel action accounts for anti-seizure effects confirmed in drug-induced seizure models.^[16]

CBC also elevates endocannabinoid tone through two routes: inhibition of the enzyme that degrades palmitoylethanolamide (NAAA) and blockade of anandamide cellular uptake.^[1] Both actions amplify endogenous anti-inflammatory signaling without direct CB1 engagement. In mice, CBC inhibited MAO-A (MAO-A) at 20 mg/kg, contributing to antidepressant-like behavioral effects comparable to imipramine.^[17]

Pharmacokinetics

No human pharmacokinetic studies for isolated CBC have been published. Bioavailability, peak plasma concentration, half-life, and volume of distribution in humans are entirely unknown. All data derive from rat models and laboratory preparations.

In rats, intestinal lymphatic transport plays a major role in oral CBC absorption, facilitated by the molecule's lipophilicity and planar structure.^[11] Nanoemulsion formulation increased lymphatic bioavailability 3-fold and portal vein bioavailability 8-fold compared to oil.

Co-administration with CBD in rats increased the plasma levels of both compounds without altering time to peak,^[18] consistent with competition at shared metabolic enzymes. The major human liver metabolite is 2'-hydroxycannabicitran, a novel oxidized structure with no significant activity at CB1 or CB2 receptors.^[19]

Despite serving as a substrate for multiple liver enzymes, CBC does not appear to significantly inhibit their activity^[7] — meaning it is unlikely to cause dangerous elevations of co-administered drug levels through metabolic interference.

Where it acts

CBC's neural effects operate through two primary pathways outside the classical endocannabinoid system. TRPA1 channels on pain-sensing nerve fibers undergo activation followed by prolonged desensitization, functionally silencing nociceptive C-fibers.^[1] In rats, CBC modulates descending pain control through the rostral ventromedial medulla and periaqueductal gray — key brain regions that gate pain signals traveling up from the body.^[20]

At GABA_A receptors, CBC enhances inhibitory neurotransmission via a binding site on the β2 subunit distinct from both the benzodiazepine and neurosteroid sites.^[2] This pharmacologically novel mechanism accounts for anti-seizure effects observed in animal models^[16] and suggests a mode of cortical inhibition unlike existing GABAergic drugs.

Why it matters

CBC's activity maps onto the "endocannabinoidome" — an expanded framework encompassing TRP channels, lipid mediators, and receptors beyond classical CB1/CB2 signaling. Through NAAA inhibition and anandamide reuptake blockade,^[1] CBC amplifies endogenous anti-inflammatory and analgesic signaling without engaging CB1 directly. This positions it as a modulator of broad lipid signaling tone rather than a single-target drug.

Direct experimental support for the entourage effect hypothesis — the idea that cannabinoids and terpenes act synergistically — comes from CBC's efficacy at subtherapeutic doses when combined with other cannabinoids^[21] and its synergy with β-caryophyllene.^[22][23]

Toxicity

No lethal dose has been determined for CBC in any species. No human adverse event reports, overdose cases, or post-market safety signals for isolated CBC have been identified.

Psychological risks

CBC does not produce psychoactive or intoxicating effects. It does not generate THC-like responses in trained animals at doses up to 30 mg/kg^[24] and produces no cannabimimetic effects in drug discrimination assays.^[6] No psychiatric adverse events, psychotomimetic effects, or cognitive impairment have been reported in any study.

CBC's GABA_A modulation raises a theoretical concern regarding sedation or cognitive blunting at high doses, analogous to other GABAergic agents. This has not been investigated.

Tolerance and dependence

No published studies on CBC tolerance, cross-tolerance, physical dependence, or withdrawal exist. This absence is consistent with CBC's negligible CB1 activity — CB1 receptor downregulation being the primary driver of cannabinoid tolerance.

CBC did not alter the interoceptive effects of THC in trained animals^[24] and showed no cannabimimetic properties,^[6] suggesting minimal abuse potential. No reinforcing properties, self-administration behavior, or conditioned place preference data have been published.

Drug interactions

CBC is metabolized by multiple liver enzymes,^[28] making it vulnerable to interactions from drugs that inhibit or accelerate those enzymes. Strong enzyme inhibitors (e.g., ketoconazole for CYP3A4, fluvoxamine for CYP1A2) could slow CBC clearance and raise its plasma levels. Strong inducers (e.g., rifampin) could accelerate its breakdown.

CBC does not significantly inhibit liver metabolic enzymes,^[7] making it less likely than CBD to cause dangerous elevations of co-administered medication levels.

CBC + CBD co-administration in rats increased mutual plasma levels without altering time to peak,^[18] consistent with competitive metabolism at shared enzymes. This interaction has not been confirmed in humans. safety citation needed

CBC potentiated CNS depressant-induced sedation in mice through a pharmacodynamic mechanism.^[7] Given its GABA_A activity,^[2] additive sedation with alcohol, benzodiazepines, barbiturates, and opioids is plausible. safety citation needed

CBC synergized with β-caryophyllene in cancer cell models^[22] and achieved therapeutic effects at subtherapeutic doses only in combination with CBD, CBDV, and CBG.^[21][23] These entourage interactions mean CBC's effects in full-spectrum cannabis products may differ substantially from isolated CBC.

Contraindications

No substance-specific contraindication data exist for CBC. The following are inferred from mechanism of action and class effects:

Absolute (inferred):

• Cannabinoid hypersensitivity: Individuals with known allergic reactions to cannabis-derived compounds should avoid CBC.

Relative (inferred):

• Concurrent CNS depressant use: CBC's pharmacodynamic potentiation of sedatives^[7] and GABA_A activity^[2] suggest additive sedation risk with benzodiazepines, barbiturates, opioids, and alcohol. safety citation needed
• Drugs metabolized by shared liver enzymes: Competitive substrate interactions may alter levels of both CBC and co-administered drugs.^[28]
• Pregnancy and lactation: Antigonadal effects observed across the cannabinoid class.^[26] No reproductive studies specific to CBC exist.
• Complex seizure disorders: While CBC demonstrated anti-seizure effects via GABA_A modulation, no human dosing or safety data exist. Interaction with existing anti-epileptic medications is unpredictable.

All contraindications are inferred from preclinical evidence. No human clinical data support or refute any specific contraindication.

CBC is not specifically scheduled under any major international drug control treaty. It is absent from the United Nations Single Convention on Narcotic Drugs (1961) and the Convention on Psychotropic Substances (1971). Its non-psychoactive, non-intoxicating profile has not triggered scheduling by any national drug control authority identified in the research literature.

In the United States, hemp-derived CBC is federally legal under the Agriculture Improvement Act of 2018 (2018 Farm Bill), provided the source plant material contains less than 0.3% Δ⁹-THC by dry weight.^[29] CBC is not listed as a controlled substance by the Drug Enforcement Administration (DEA) and does not fall under Federal Analogue Act provisions due to its non-psychoactive nature.

CBC products are commercially marketed in the United States and other jurisdictions where hemp-derived cannabinoids are legal. Product purity — particularly absence of Δ⁹-THC contamination above legal thresholds — is a regulatory compliance consideration. CBC does not produce cross-reactivity with standard THC urine drug screens due to its distinct metabolite profile.